07:00 , Sep 10, 2012 |  BC Week In Review  |  Clinical News

ALN-RSV01: Final Phase II data

Final data from 87 lung transplant patients in the intent-to-treat (ITT) population of a double-blind, international Phase IIb trial showed once-daily 0.6 mg/kg inhaled ALN-RSV01 for 5 days plus standard of care met the secondary...
07:00 , Jun 4, 2012 |  BC Week In Review  |  Clinical News

ALN-RSV01: Phase IIb data

Top-line data from 87 lung transplant patients in the intent-to-treat (ITT) population of a double-blind, international Phase IIb trial showed that once-daily 0.6 mg/kg inhaled ALN-RSV01 for 5 days plus standard of care missed the...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

ALN-RSV01: Completed Phase IIb enrollment

Alnylam completed enrollment of about 90 RSV-infected lung transplant patients in the double-blind, placebo-controlled, international Phase IIb trial evaluating 0.6 mg/kg inhaled ALN-RSV01 once daily for 5 days. The compound is delivered with the eFlow...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Clinical News

ALN-RSV01: Final Phase II data

Alnylam previously reported that ALN-RSV01 was well tolerated and reduced infection rate by 38% vs. placebo (see BioCentury, Jan. 28, 2008, & March 3, 2008). Cubist and Alnylam partnered to co-develop and commercialize Alnylam's ALN-RSV...
08:00 , Mar 1, 2010 |  BC Week In Review  |  Clinical News

ALN-RSV01: Phase IIb started

Alnylam began a double-blind, placebo-controlled, international Phase IIb trial to evaluate 0.6 mg/kg inhaled ALN-RSV01 given once daily for 5 days in about 76 patients. The compound is delivered with the eFlow Nebulizer System from...
07:00 , Jul 27, 2009 |  BC Week In Review  |  Clinical News

ALN-RSV01: Final Phase II data

Final data from 24 lung transplant patients with RSV in a double-blind, placebo-controlled, international Phase II trial showed that inhaled ALN-RSV01 was well tolerated with no serious adverse events and all patients surviving to 90...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Clinical News

ALN-RSV01: Phase II data

Data from a double-blind, placebo-controlled Phase II trial in 24 lung transplant patients infected with RSV showed that inhaled ALN-RSV01 was well tolerated at 30 days post-treatment, with no drug-related serious adverse events or discontinuations....
07:00 , May 18, 2009 |  BC Week In Review  |  Clinical News

ALN-RSV01: Completed Phase II enrollment

Alnylam completed enrollment of 24 patients in a double-blind, placebo-controlled, U.S. and Australian Phase II trial (ALN-RSV01-106) evaluating inhaled ALN-RSV01 given once daily for 3 days. Cubist and Alnylam partnered to co-develop and commercialize Alnylam's...